Fund V. L.P. Omega Sells 4,436 Shares of Morphic Holding, Inc. (NASDAQ:MORF) Stock

Morphic Holding, Inc. (NASDAQ:MORF) Director Fund V. L.P. Omega sold 4,436 shares of Morphic stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of $35.57, for a total transaction of $157,788.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

MORF traded down $0.10 during trading on Tuesday, hitting $34.33. The stock had a trading volume of 3,416 shares, compared to its average volume of 139,777. The company has a market capitalization of $1.07 billion, a PE ratio of -21.87 and a beta of 1.01. Morphic Holding, Inc. has a twelve month low of $9.90 and a twelve month high of $41.00. The stock has a 50 day simple moving average of $33.69 and a two-hundred day simple moving average of $29.90.

Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of Morphic from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Tuesday, November 17th. Royal Bank of Canada lifted their price objective on shares of Morphic from $35.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, February 2nd.

Institutional investors and hedge funds have recently made changes to their positions in the business. Lazard Asset Management LLC acquired a new stake in shares of Morphic during the fourth quarter worth $66,000. Citigroup Inc. lifted its stake in shares of Morphic by 327.3% during the fourth quarter. Citigroup Inc. now owns 2,816 shares of the company’s stock worth $94,000 after buying an additional 2,157 shares during the period. BNP Paribas Arbitrage SA lifted its stake in shares of Morphic by 208.0% during the third quarter. BNP Paribas Arbitrage SA now owns 3,638 shares of the company’s stock worth $99,000 after buying an additional 2,457 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Morphic by 10.5% during the third quarter. JPMorgan Chase & Co. now owns 5,105 shares of the company’s stock worth $140,000 after buying an additional 487 shares during the period. Finally, Virtus ETF Advisers LLC acquired a new stake in shares of Morphic during the fourth quarter worth $295,000. Institutional investors own 61.49% of the company’s stock.

Morphic Company Profile

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avÃ6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4Ã7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD).

Read More: Dividend Kings